Skip to main content
. 2016 Jan 22;310(7):H891–H898. doi: 10.1152/ajpheart.00963.2015

Fig. 4.

Fig. 4.

Clonidine attenuates the increase in MAP and heart rate caused by MK-5046. Effects of intravenous MK-5046 (1 mg/kg in 5% dimethylacetamide in saline) were studied in anesthetized wild-type (WT) and Brs3−/y (KO) mice at 12–16 wk of age. A and D: baseline MAP and heart rate from 12 to 2 min before infusion. *P < 0.05 vs. WT. B and E: change in MAP and heart rate response to MK-5046 or vehicle (Veh) at 1 to 5 min after infusion. *P < 0.05 MK-5046 vs. vehicle; †P < 0.05, genotype effect within MK-5046 treatment. C and F: in wild-type mice, effect of pretreatment with clonidine (40 μg/kg ip) or saline given 1 h before MK-5046 on MAP and heart rate response to MK-5046 or vehicle (Veh) at 1 to 5 min after infusion. Data are means ± SE; n = 6–7/group. *P < 0.05 MK-5046 vs. vehicle; †P < 0.05, clonidine effect within MK-5046 treatment.